Systemic protein synthesis pathways via glutamine availability

Systemic protein synthesis pathways via glutamine availability refers to the integrated biological process where the abundance of the amino acid glutamine dictates the rate of mRNA translation and protein production across various tissues (Durán et al., 2012, Mol Cell). Glutamine acts as a key signaling molecule and metabolic substrate; its intracellular levels are sensed by the mechanistic target of rapamycin complex 1 (mTORC1), which serves as a master regulator of protein synthesis (Nicklin et al., 2009, Science). In pathological states like cancer, tumors often exhibit glutamine addiction, upregulating transporters like SLC1A5 and enzymes like glutaminase (GLS) to fuel rapid growth (Wise & Thompson, 2010, Trends Biochem Sci). Conversely, in systemic conditions such as cachexia or critical illness, glutamine depletion can lead to impaired protein synthesis and muscle loss (Cruzat et al., 2018, Nutrients). Therapeutic strategies targeting this pathway often focus on inhibiting glutamine uptake or its conversion to glutamate to starve cancer cells or modulate immune responses (Hensley et al., 2013, J Clin Invest). By modulating these pathways, researchers aim to restore metabolic balance or selectively inhibit the growth of nutrient-dependent pathologies.

Other names

Glutamine-mTORC1 signaling axisGlutamine-dependent translation regulationAmino acid-sensing protein synthesis pathwayGlutamine-mediated metabolic signaling

Modulation of glutamine availability through inhibition of membrane transporters (e.g., SLC1A5), enzymatic conversion (e.g., GLS), or downstream nutrient sensing (e.g., mTORC1) to control protein translation rates.